ImmunoGen, Inc. (IMGN) Announces Conference Call to Discuss its First Quarter Fiscal Year 2013 Financial Results
10/19/2012 9:01:02 AM
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 26, 2012, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2012 – the first quarter of the Company’s 2013 fiscal year. Management also will provide an update on the Company and more information about the economic terms of the trastuzumab emtansine (T-DM1)-related license with Genentech, a member of the Roche Group.